Eiry Roberts - 12 Feb 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Reporting relationship: Chief Medical Officer
Issuer ticker: NBIX
Reported as of: 12 Feb 2025
Net transaction value: -$258,264
SEC form: 4
Accepted by SEC: 14 Feb 2025, 18:42:06 UTC
Prior SEC filing: 12 Feb 2025
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Darin Lippoldt, Attorney-in-Fact

Key filing fact

Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 14 Feb 2025.

Key facts

This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
11 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 14 Feb 2025, 18:42.

Change

Previous filing in this sequence was filed on 12 Feb 2025.
Current net transaction value: -$258,264.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBIX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,113
Change %: +6.4%
Price: $0.000000
Shares after: 35,366
Date: 13 Feb 2025
Ownership: Direct

NBIX transaction

Common Stock

Sale

Transaction value: $130,232
Shares: -1,114
Change %: -3.1%
Price: $116.90
Shares after: 34,252
Date: 13 Feb 2025
Ownership: Direct
Footnotes: F1, F2

NBIX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,120
Change %: +3.3%
Price: $0.000000
Shares after: 35,372
Date: 13 Feb 2025
Ownership: Direct

NBIX transaction

Common Stock

Sale

Transaction value: $70,510
Shares: -604
Change %: -1.7%
Price: $116.74
Shares after: 34,768
Date: 13 Feb 2025
Ownership: Direct
Footnotes: F3, F4

NBIX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,372
Change %: +3.9%
Price: $0.000000
Shares after: 36,140
Date: 13 Feb 2025
Ownership: Direct

NBIX transaction

Common Stock

Sale

Transaction value: $57,521
Shares: -500
Change %: -1.4%
Price: $115.04
Shares after: 35,640
Date: 14 Feb 2025
Ownership: Direct
Footnotes: F5, F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBIX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +43,261
Change %
Price: $0.000000
Shares after: 43,261
Date: 12 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 43,261
Exercise price: $117.18
Footnotes: F7

NBIX transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +8,108
Change %
Price: $0.000000
Shares after: 8,108
Date: 12 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,108
Exercise price
Footnotes: F8, F9

NBIX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -2,113
Change %: -33%
Price: $0.000000
Shares after: 4,227
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,113
Exercise price
Footnotes: F8, F10

NBIX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -1,120
Change %: -25%
Price: $0.000000
Shares after: 3,363
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,120
Exercise price
Footnotes: F8, F11

NBIX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -1,372
Change %: -25%
Price: $0.000000
Shares after: 4,115
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,372
Exercise price
Footnotes: F8, F12

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 12 footnotes

Footnote F1

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F2

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.24 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F3

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Footnote F4

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $118.28. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F5

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $114.76 to $115.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F6

34,455 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.

Footnote F7

Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

Footnote F8

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.

Footnote F9

The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029.

Footnote F10

This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, and will vest as to 2,113 shares on February 13, 2026, and 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.

Footnote F11

This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, and will vest as to 1,121 shares on February 13, 2026, 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.

Footnote F12

This RSU was granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, and will vest as to 1,372 shares on February 13, 2026, 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.